-
Something wrong with this record ?
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma
L. Moreno, G. Barone, SG. DuBois, J. Molenaar, M. Fischer, J. Schulte, A. Eggert, G. Schleiermacher, F. Speleman, L. Chesler, B. Geoerger, MD. Hogarty, MS. Irwin, N. Bird, GB. Blanchard, S. Buckland, H. Caron, S. Davis, B. De Wilde, HE. Deubzer,...
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Molecular Targeted Therapy methods trends MeSH
- Child MeSH
- Therapies, Investigational methods trends MeSH
- Protein Kinase Inhibitors isolation & purification therapeutic use MeSH
- Congresses as Topic MeSH
- Medical Oncology methods organization & administration trends MeSH
- Humans MeSH
- Brain Neoplasms drug therapy pathology MeSH
- Neuroblastoma drug therapy pathology MeSH
- Drug Discovery methods organization & administration trends MeSH
- Pediatrics methods organization & administration trends MeSH
- Antineoplastic Agents isolation & purification therapeutic use MeSH
- Drug Development * methods organization & administration trends MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Geographicals
- Europe MeSH
Only one class of targeted agents (anti-GD2 antibodies) has been incorporated into front-line therapy for neuroblastoma since the 1980s. The Neuroblastoma New Drug Development Strategy (NDDS) initiative commenced in 2012 to accelerate the development of new drugs for neuroblastoma. Advances have occurred, with eight of nine high-priority targets being evaluated in paediatric trials including anaplastic lymphoma kinase inhibitors being investigated in front-line, but significant challenges remain. This article reports the conclusions of the second NDDS forum, which expanded across the Atlantic to further develop the initiative. Pre-clinical and clinical data for 40 genetic targets and mechanisms of action were prioritised and drugs were identified for early-phase trials. Strategies to develop drugs targeting TERT, telomere maintenance, ATRX, alternative lengthening of telomeres (ALT), BRIP1 and RRM2 as well as direct targeting of MYCN are high priority and should be championed for drug discovery. Promising pre-clinical data suggest that targeting of ALT by ATM or PARP inhibition may be potential strategies. Drugs targeting CDK2/9, CDK7, ATR and telomere maintenance should enter paediatric clinical development rapidly. Optimising the response to anti-GD2 by combinations with chemotherapy, targeted agents and other immunological targets are crucial. Delivering this strategy in the face of small patient cohorts, genomically defined subpopulations and a large number of permutations of combination trials, demands even greater international collaboration. In conclusion, the NDDS provides an internationally agreed, biologically driven selection of prioritised genetic targets and drugs. Improvements in the strategy for conducting trials in neuroblastoma will accelerate bringing these new drugs more rapidly to front-line therapy.
Berlin Institute of Health Berlin Germany
Center for Medical Genetics Ghent Belgium
Center for Molecular Medicine Cologne Medical Faculty University of Cologne Cologne Germany
Department of Biochemistry and Molecular Biology University of Wuerzburg Germany
Department of Cell Biology UT Southwestern Medical Center Dallas TX USA
Department of Clinical Research Gustave Roussy Paris Sud University Paris France
Department of Oncology University of Cambridge UK
Department of Paediatric Haemaology Oncology Our Lady's Children's Hospital Dublin Ireland
Department of Paediatric Oncology Great Ormond Street Hospital for Children London UK
Department of Pediatric Oncology and Hematology Charité University Hospital Berlin Germany
Department of Pharmacy and Biotechnology University of Bologna Bologna Italy
Division of Clinical Studies and Cancer Therapeutics The Institute of Cancer Research Sutton UK
Experimental Pediatric Oncology University Children's Hospital Cologne Germany
German Cancer Consortium Berlin Germany
Hoffmann La Roche Ltd Basel Switzerland
Paediatric Haematology and Oncology Division Hospital Universitari Vall d'Hebron Barcelona Spain
Perelman School of Medicine University of Pennsylvania USA
Princess Máxima Centre for Paediatric Oncology Utrecht The Netherlands
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21012189
- 003
- CZ-PrNML
- 005
- 20210507102126.0
- 007
- ta
- 008
- 210420s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejca.2020.05.010 $2 doi
- 035 __
- $a (PubMed)32653773
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Moreno, Lucas $u Paediatric Haematology & Oncology Division, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Electronic address: lucas.moreno@vhebron.net
- 245 10
- $a Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma / $c L. Moreno, G. Barone, SG. DuBois, J. Molenaar, M. Fischer, J. Schulte, A. Eggert, G. Schleiermacher, F. Speleman, L. Chesler, B. Geoerger, MD. Hogarty, MS. Irwin, N. Bird, GB. Blanchard, S. Buckland, H. Caron, S. Davis, B. De Wilde, HE. Deubzer, E. Dolman, M. Eilers, RE. George, S. George, Š. Jaroslav, JM. Maris, L. Marshall, M. Merchant, P. Mortimer, C. Owens, A. Philpott, E. Poon, JW. Shay, R. Tonelli, D. Valteau-Couanet, G. Vassal, JR. Park, ADJ. Pearson
- 520 9_
- $a Only one class of targeted agents (anti-GD2 antibodies) has been incorporated into front-line therapy for neuroblastoma since the 1980s. The Neuroblastoma New Drug Development Strategy (NDDS) initiative commenced in 2012 to accelerate the development of new drugs for neuroblastoma. Advances have occurred, with eight of nine high-priority targets being evaluated in paediatric trials including anaplastic lymphoma kinase inhibitors being investigated in front-line, but significant challenges remain. This article reports the conclusions of the second NDDS forum, which expanded across the Atlantic to further develop the initiative. Pre-clinical and clinical data for 40 genetic targets and mechanisms of action were prioritised and drugs were identified for early-phase trials. Strategies to develop drugs targeting TERT, telomere maintenance, ATRX, alternative lengthening of telomeres (ALT), BRIP1 and RRM2 as well as direct targeting of MYCN are high priority and should be championed for drug discovery. Promising pre-clinical data suggest that targeting of ALT by ATM or PARP inhibition may be potential strategies. Drugs targeting CDK2/9, CDK7, ATR and telomere maintenance should enter paediatric clinical development rapidly. Optimising the response to anti-GD2 by combinations with chemotherapy, targeted agents and other immunological targets are crucial. Delivering this strategy in the face of small patient cohorts, genomically defined subpopulations and a large number of permutations of combination trials, demands even greater international collaboration. In conclusion, the NDDS provides an internationally agreed, biologically driven selection of prioritised genetic targets and drugs. Improvements in the strategy for conducting trials in neuroblastoma will accelerate bringing these new drugs more rapidly to front-line therapy.
- 650 _2
- $a protinádorové látky $x izolace a purifikace $x terapeutické užití $7 D000970
- 650 _2
- $a nádory mozku $x farmakoterapie $x patologie $7 D001932
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a kongresy jako téma $7 D003226
- 650 12
- $a vyvíjení léků $x metody $x organizace a řízení $x trendy $7 D000076722
- 650 _2
- $a objevování léků $x metody $x organizace a řízení $x trendy $7 D055808
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lékařská onkologie $x metody $x organizace a řízení $x trendy $7 D008495
- 650 _2
- $a cílená molekulární terapie $x metody $x trendy $7 D058990
- 650 _2
- $a neuroblastom $x farmakoterapie $x patologie $7 D009447
- 650 _2
- $a pediatrie $x metody $x organizace a řízení $x trendy $7 D010372
- 650 _2
- $a inhibitory proteinkinas $x izolace a purifikace $x terapeutické užití $7 D047428
- 650 _2
- $a experimentální terapie $x metody $x trendy $7 D035703
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Barone, Giuseppe $u Department of Paediatric Oncology, Great Ormond Street Hospital for Children, London, UK
- 700 1_
- $a DuBois, Steven G $u Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA
- 700 1_
- $a Molenaar, Jan $u Princess Máxima Centre for Paediatric Oncology, Utrecht, The Netherlands
- 700 1_
- $a Fischer, Matthias $u Experimental Pediatric Oncology, University Children's Hospital, Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne, Cologne, Germany
- 700 1_
- $a Schulte, Johannes $u Department of Pediatric Oncology & Hematology, Charité University Hospital, Berlin, Germany
- 700 1_
- $a Eggert, Angelika $u Department of Pediatric Oncology & Hematology, Charité University Hospital, Berlin, Germany; German Cancer Consortium (DKTK Berlin), Berlin, Germany; Berlin Institute of Health (BIH), Berlin, Germany
- 700 1_
- $a Schleiermacher, Gudrun $u SIREDO, Department of Paediatric, Adolescents and Young Adults Oncology and INSERM U830, Institut Curie, Paris, France
- 700 1_
- $a Speleman, Frank $u Center for Medical Genetics Ghent (CMGG), Department of Biomolecular Medicine, Cancer Research Institute Ghent (CRIG), Belgium
- 700 1_
- $a Chesler, Louis $u Paediatric Drug Development, Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK; Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK
- 700 1_
- $a Geoerger, Birgit $u Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, University Paris-Saclay & Inserm U1015, Villejuif, France
- 700 1_
- $a Hogarty, Michael D $u Division of Oncology, Children's Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania, USA; Perelman School of Medicine, University of Pennsylvania, USA
- 700 1_
- $a Irwin, Meredith S $u Department of Paediatrics, Medical Biophysics and Laboratory Medicine & Pathobiology, The Hospital for Sick Kids, Toronto, Canada
- 700 1_
- $a Bird, Nick $u Solving Kids' Cancer, UK and National Cancer Research Institute Children's Cancer & Leukaemia Clinical Studies Group, UK
- 700 1_
- $a Blanchard, Guy B $u Neuroblastoma UK & Department of Physiology, Development & Neuroscience, University of Cambridge, UK
- 700 1_
- $a Buckland, Sean $u Pfizer Ltd, Surrey, UK
- 700 1_
- $a Caron, Hubert $u Hoffmann-La Roche Ltd, Basel, Switzerland
- 700 1_
- $a Davis, Susan $u Cyclacel Limited, Dundee, UK
- 700 1_
- $a De Wilde, Bram $u Center for Medical Genetics Ghent (CMGG), Department of Biomolecular Medicine, Cancer Research Institute Ghent (CRIG), Belgium
- 700 1_
- $a Deubzer, Hedwig E $u Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne, Cologne, Germany
- 700 1_
- $a Dolman, Emmy $u Department of Translational Research, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
- 700 1_
- $a Eilers, Martin $u Department of Biochemistry and Molecular Biology, University of Wuerzburg, Germany
- 700 1_
- $a George, Rani E $u Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA
- 700 1_
- $a George, Sally $u Paediatric Drug Development, Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK; Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK
- 700 1_
- $a Jaroslav, Štěrba $u Pediatric Oncology Department, University Hospital Brno, School of Medicine Masaryk University Brno, Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, ICRC Brno, St Anna University Hospital Brno, Czech Republic
- 700 1_
- $a Maris, John M $u Division of Oncology, Children's Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania, USA; Perelman School of Medicine, University of Pennsylvania, USA
- 700 1_
- $a Marshall, Lynley $u Paediatric Drug Development, Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK; Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK
- 700 1_
- $a Merchant, Melinda $u Astrazeneca, Early Clinical Projects, Oncology Translation Medicines Unit, Innovative Medicines Unit, Cambridge, UK
- 700 1_
- $a Mortimer, Peter $u Astrazeneca, Early Clinical Projects, Oncology Translation Medicines Unit, Innovative Medicines Unit, Cambridge, UK
- 700 1_
- $a Owens, Cormac $u Department of Paediatric Haemaology/Oncology, Our Lady's Children's Hospital, Dublin, Ireland
- 700 1_
- $a Philpott, Anna $u Department of Oncology, University of Cambridge, UK
- 700 1_
- $a Poon, Evon $u Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK
- 700 1_
- $a Shay, Jerry W $u Department of Cell Biology, UT Southwestern Medical Center, Dallas, TX, USA
- 700 1_
- $a Tonelli, Roberto $u Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
- 700 1_
- $a Valteau-Couanet, Dominique $u Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, University Paris-Saclay & Inserm U1015, Villejuif, France
- 700 1_
- $a Vassal, Gilles $u Department of Clinical Research, Gustave Roussy, Paris-Sud University, Paris, France
- 700 1_
- $a Park, Julie R $u Department of Pediatrics, University of Washington School of Medicine and Center for Clinical and Translational Research, Seattle Children's Hospital, USA
- 700 1_
- $a Pearson, Andrew D J $u Paediatric Drug Development, Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK; Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK
- 773 0_
- $w MED00009626 $t European journal of cancer (Oxford, England : 1990) $x 1879-0852 $g Roč. 136, č. - (2020), s. 52-68
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32653773 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507102125 $b ABA008
- 999 __
- $a ok $b bmc $g 1650543 $s 1132568
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 136 $c - $d 52-68 $e 20200709 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
- LZP __
- $a Pubmed-20210420
